Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Illumina

Biotech & Life Sciences · San Diego, United States · Founded 1998 · IPO 2000 Decacorn

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation
$21B
Market cap · May/2026
Revenue
$4.34B
Latest reported FY
EBITDA
$1.37B
Latest reported FY

Sequencing and array based solutions for genetic research

Investors

12 investors on Illumina's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 8 investors entered at this stage
CW Group Holdings
Chevron Technology Ventures
Lombard Odier
Tredegar Investments
State Farm
Chase Capital Partners
Dow
The Tisch Family
Series B+ 4 investors entered at this stage
ARCH Venture Partners
University of Utah
Tufts University
Venrock

Global footprint

Where Illumina has talent and traffic

AI talent share
1.0% of workforce is AI talent
(92 of 9,578 staff)
Core AI520.54%
Other AI400.42%
Non-AI workforce9,48699.04%
Workforce by country
49 countries with
team presence
🇺🇸 United States59%
🇸🇬 Singapore11.9%
🇬🇧 United Kingdom9.1%
🇮🇳 India3.2%
🇨🇳 China2.3%
Top 5 of 49 shown
Web traffic by country
770K monthly visits
across markets
🇺🇸 United States40.4%
🇬🇧 United Kingdom6%
🇯🇵 Japan5.4%
🇧🇷 Brazil2.6%
🇨🇦 Canada2.6%
Top 5 markets shown

Patent intelligence

$2.7B patent portfolio · 2,241 active families

Estimated portfolio value
$2.7B
13.3% of market cap · 4.4× the top peer BGI ($627M)
2,241 active patent families
Where Illumina innovates BioinformaticsMolecular biologyNucleic acidNucleotideComputational biology

Where Illumina concentrates vs peers

Each axis is a top-10 topic across Illumina and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Illumina's 145 investments and acquisitions.

Every disclosed deal where Illumina appeared as a backer or acquirer, 2006–2026. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

145 deals across Illumina's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Illumina deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Illumina's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        145 of 145 deals

        Sentiment on X

        What X is saying about Illumina

        An AI-synthesized read of the highest-engagement posts about Illumina on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Illumina on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.